Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
41336 Results Found
Workbook highlights importance of gathering employee feedback for organizational growth
The AHA, in partnership with Press Ganey, Dec. 16 released the third in a series of workbooks leaders can use to understand and overcome challenges in engaging their workforce.
Blog: Putting 340B Program Growth in Context
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.
Report finds increasing concentration in commercial health, MA insurance markets
The American Medical Association Dec. 16 released its latest annual report on health insurance competition, finding that 97% of commercial markets were highly concentrated in 2024.
2025 National Governance Report: Chapter 3
The American Hospital Association (AHA) is pleased to release Chapter 3 of its 2025 National Governance Report to the field.
2025 National Governance Report
The American Hospital Association (AHA) is pleased to release Chapter 1 of its 2025 National Governance Report to the field.
Trustee Involvement
Trustee Involvement The AHA has numerous avenues for trustee involvement and participation in the Association’s governance, grassroots advocacy, policy development and field leadershi
Committee on Governance
The Committee on Governance (COG) is one of several advisory committees of the AHA Board. The COG represents AHA’s trustees by participating in the AHA’s advocacy, policy, and resource development, with a particular focus on strategic opportunities.
Annual Meeting - Homepage
Issue Landing Page
Join executive leaders from the nation’s top hospitals and health systems at the 2026 AHA Annual Membership Meeting, in Washington, D.C.
Putting 340B Program Growth in Context
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.